Weighted Average Number of Shares Outstanding, Diluted of Rani Therapeutics Holdings, Inc. from Q3 2021 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Rani Therapeutics Holdings, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted history and change rate from Q3 2021 to Q3 2025.
  • Rani Therapeutics Holdings, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 46,444,000, a 61% increase year-over-year.
  • Rani Therapeutics Holdings, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 28,476,000, a 12% increase from 2023.
  • Rani Therapeutics Holdings, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 25,505,000, a 7.1% increase from 2022.
  • Rani Therapeutics Holdings, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 23,817,000.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Rani Therapeutics Holdings, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 46,444,000 +17,608,000 +61% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 36,542,000 +10,218,000 +39% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 33,440,000 +7,406,000 +28% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 28,476,000 +2,971,000 +12% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 28,836,000 +3,284,000 +13% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 26,324,000 +979,000 +3.9% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 26,034,000 +794,000 +3.1% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 25,505,000 +1,688,000 +7.1% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 25,552,000 +1,084,000 +4.4% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 25,345,000 +974,000 +4% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 25,240,000 +3,831,000 +18% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 23,817,000 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 24,468,000 +5,031,000 +26% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 24,371,000 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 21,409,000 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q3 2021 19,437,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3

Rani Therapeutics Holdings, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 28,476,000 +2,971,000 +12% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 25,505,000 +1,688,000 +7.1% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 23,817,000 +23,797,466 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
2021 19,534* 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.